GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (XTER:DC4) » Definitions » Debt-to-EBITDA

DexCom (XTER:DC4) Debt-to-EBITDA : 3.42 (As of Mar. 2024)


View and export this data going back to 1990. Start your Free Trial

What is DexCom Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DexCom's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €19 Mil. DexCom's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2,364 Mil. DexCom's annualized EBITDA for the quarter that ended in Mar. 2024 was €698 Mil. DexCom's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.42.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DexCom's Debt-to-EBITDA or its related term are showing as below:

XTER:DC4' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.97   Med: 1.39   Max: 5.72
Current: 2.6

During the past 13 years, the highest Debt-to-EBITDA Ratio of DexCom was 5.72. The lowest was -16.97. And the median was 1.39.

XTER:DC4's Debt-to-EBITDA is ranked worse than
68.29% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs XTER:DC4: 2.60

DexCom Debt-to-EBITDA Historical Data

The historical data trend for DexCom's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Debt-to-EBITDA Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.44 4.88 5.72 3.79 2.83

DexCom Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 4.04 2.32 2.14 3.42

Competitive Comparison of DexCom's Debt-to-EBITDA

For the Medical Devices subindustry, DexCom's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DexCom's Debt-to-EBITDA falls into.



DexCom Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DexCom's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.349 + 2359.349) / 840.614
=2.83

DexCom's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.044 + 2363.848) / 697.728
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


DexCom  (XTER:DC4) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


DexCom Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DexCom's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (XTER:DC4) Business Description

Traded in Other Exchanges
Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

DexCom (XTER:DC4) Headlines

No Headlines